GLP-1 drugs on every 2026 Connecticut Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 11 stand-alone Part D plans in Connecticut cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
11 plans, cheapest premium first. Scroll sideways for all of them →
| Drug | Humana Basic Rx Plan$8.40/moS5884-102 | Wellcare Value Script$16.40/moS4802-137 | Blue MedicareRx Value Plus$20.70/moS2893-001 | Wellcare Classic$21.70/moS4802-076 | SilverScript Choice$32.70/moS5601-004 | AARP Medicare Rx Saver from UHC$38.70/moS5921-348 | Humana Value Rx Plan$73.60/moS5884-182 | Humana Premier Rx Plan$138.60/moS5884-149 | HealthSpring Assurance Rx$139.30/moS5617-008 | AARP Medicare Rx Preferred from UHC$155.10/moS5921-385 | Blue MedicareRx Premier$238.60/moS2893-003 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ozempicsemaglutide injection | Tier 3PA25%QL 3/28d | Tier 6PA$11.00QL 3/28d | Tier 3PA17%QL 3/28d | Tier 3PA25%QL 3/28d | Tier 3PA19%QL 3/28d | Tier 3PA17%QL 3/28d | Tier 3PA18%QL 3/28d | Tier 3PA$45.00QL 3/28d | Tier 3PA21%QL 3/28d | Tier 3PA15%QL 3/28d | Tier 3PA$30.00QL 3/28d |
| Mounjarotirzepatide injection | Tier 3PA25%QL 2/28d | Tier 6PA$11.00QL 2/28d | Tier 3PA17%QL 2/28d | Tier 3PA25%QL 2/28d | Tier 3PA19%QL 2/28d | Tier 3PA17%QL 2/28d | Tier 3PA18%QL 2/28d | Tier 3PA$45.00QL 2/28d | Tier 3PA21%QL 2/28d | Tier 3PA15%QL 2/28d | Tier 3PA$30.00QL 2/28d |
| Trulicitydulaglutide injection | Not covered | Tier 6PA$11.00QL 2/28d | Tier 3PA17%QL 2/28d | Tier 3PA25%QL 2/28d | Tier 3PA19%QL 2/28d | Tier 3PA17%QL 2/28d | Not covered | Not covered | Tier 3PA21%QL 2/28d | Tier 3PA15%QL 2/28d | Tier 3PA$30.00QL 2/28d |
| Ozempic tabletsoral semaglutide, formerly Rybelsus | Not covered | Tier 6PA$11.00QL 30/30d | Tier 3PA17%QL 30/30d | Tier 3PA25%QL 30/30d | Tier 3PA19%QL 30/30d | Tier 3PA17%QL 30/30d | Not covered | Not covered | Tier 3PA21%QL 30/30d | Tier 3PA15%QL 30/30d | Tier 3PA$30.00QL 30/30d |
| Wegovysemaglutide, weight | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Zepboundtirzepatide, weight | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Victozaliraglutide | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| liraglutidegeneric Victoza | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Saxendaliraglutide, weight | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). | ||||||||||
| Byettaexenatide | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). | ||||||||||
| Bydureon BCiseexenatide extended-release | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). | ||||||||||
| orforglipronoral GLP-1, approved 2026 | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). | ||||||||||
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.